Clinical operations

Before the First Participant Arrives: Five Oncology Site Readiness Checks

Use five practical checks for investigational product, staffing, laboratory logistics, systems and first-visit coordination.

By Lampgen Clinical Research

An empty infusion chair and five objects symbolizing product, staff, laboratory, systems and visit readiness.
Conceptual editorial illustration; it does not depict an observed study procedure, actual patient data or a demonstrated treatment outcome.

3 min read · estimated

Sources
Activation milestoneFirst-visit capability
A proposed readiness exercise, not an additional regulatory approval.

What the source reported

ICH E8(R1) emphasizes operational feasibility and input from people who conduct or participate in studies. [1] FDA’s investigator-responsibilities guidance addresses supervision of delegated work. [2] These principles support planning a workable first visit, but neither source establishes this five-check format as a required regulatory checklist. Activation requirements remain study-, organization- and jurisdiction-specific.

What this means for trial teams

Lampgen’s analysis: site activation and readiness for the first participant are related questions with different practical tests. Activation records whether specified approvals and prerequisites are complete. A visit walkthrough tests whether people, materials and systems will connect at the moment they are needed. Both deserve attention without confusing one measure with another.

The first check is investigational-product readiness. Ask the authorized team to confirm the program’s release and supply prerequisites, receipt and storage arrangements, accountability process and preparation pathway. Identify where to route a temperature concern, missing item or uncertainty about the planned administration. This is a coordination check, not permission to depart from pharmacy instructions or clinical requirements.

The second check is staffing continuity. Name the people responsible for the actual visit tasks, then test who covers an absence. Review the relevant training and delegation records under the site’s procedures. A backup listed on a document still needs the practical availability, access and preparation to perform the assigned activity when needed.

The third check is laboratory logistics. Trace a specimen from collection through processing, temporary storage, packaging and pickup, using the current laboratory manual. Confirm the materials and equipment the workflow requires. Include holidays, closing times and a missed courier collection in the discussion. Avoid assuming that a process available on a routine weekday works on every planned visit date.

The fourth check is usable system access. Ask the staff who will enter, review or retrieve study information to confirm that their roles work. A request submitted to a help desk is different from successful access. Consider the approved contingency process if a critical system is unavailable; the team should not improvise a new one during the visit.

The fifth check is the participant journey. Walk through consent, eligibility review, appointments, required results, procedures and departure information in the order the protocol requires. Include the investigator and the relevant site functions. Identify dependencies that could leave a participant waiting or require an avoidable return trip. Explain whom the participant can contact with questions.

Record unresolved items with an owner and a decision date. Ask which items affect the ability to proceed under the study’s requirements, and refer that decision to the authorized people. The exercise is useful because it uncovers a dependency while there is time to address it. It does not establish that all future visits will be error-free.

For oncology staffing, this creates a concrete assignment brief. A CRA can support readiness verification within the monitoring plan, while the CTM coordinates study-level dependencies. The value is preparation focused on the actual first visit and the people who must deliver it.

Sources

  1. ICH — E8(R1), General Considerations for Clinical Studies
  2. FDA — Investigator Responsibilities

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?